New Multi-Cancer Early Detection Data Presented at ASCO 2023
The study's multi-cancer early detection data show Exai's RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample.
The study's multi-cancer early detection data show Exai's RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample.
OncoHost will give a poster presentation demonstrating the accuracy of its PROphet biomarker model at the upcoming 2023 ASCO Annual Meeting.
xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients.
The American Urological Association and Society of Urologic Oncology have released the 2023 clinical practice guideline on the early detection of prostate cancer.
Read MoreBeacon Biomedical announced the availability of its BeScreened Colorectal Cancer (CRC) test at Any Lab Test Now locations across the nation.
Read MoreAdela demonstrated the ability of its genome-wide methylome enrichment platform to detect a broad set of diverse cancers in early stages.
Read MoreNew data demonstrates Exai Bio’s novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy.
Read MoreA team led by Florida State University chemists developed a new test for detecting biomarkers related to several types of cancer.
Read MoreAgilent Technologies Inc. has launched the Agilent SureSelect Cancer CGP Assay for somatic variant profiling for a range of solid tumors.
Read MoreA team from the Max Planck Institute use artificial intelligence to evaluate surgical biopsy data, creating a kind of artificial pathologist.
Read MoreResearchers say newly reported cases of cancer diagnoses declined 14.4% in 2020 compared with prior years.
Read MoreThe collaboration will cover programs to aid the development and commercialization of investigational medicines for hematologic malignancies.
Read MoreFoundation Medicine and Bristol Myers Squibb are developing the FoundationOne CDx as a companion diagnostic for repotrectinib.
Read MoreA new report shows Saudi Arabia has a high percentage of respondents who never took colon cancer tests, far higher than the global average.
Read MoreBeacon Biomedical released a colon cancer screening test designed to improve access and affordability to CRC screening as a blood draw.
Read MoreA new method of measuring tRNA in blood samples offers a simple and highly-precise alternative to invasive diagnostic and prognostic methods.
Read MoreA simple blood draw can help determine if peptide receptor radionuclide therapy is effective in a patient with neuroendocrine cancer.
Read MoreGuardant Health and Ohio State University will evaluate patient compliance with a blood-based test for colorectal cancer (CRC) screening.
Read More